Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | HINT1 | P49773 | 2/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | KRAS | P01116 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14216817 | 1.00 | CYP3A4 (0.51) | CYP3A4CYP2C9TAS1R3TAS1R1HINT1 | |
| SCHEMBL14367295 | 1.00 | CYP3A4 (0.51) | CYP3A4CYP2C9TAS1R3TAS1R1HINT1 | |
| SCHEMBL14393309 | 1.00 | CYP3A4 (0.51) | CYP3A4CYP2C9TAS1R3TAS1R1HINT1 | |
| SCHEMBL12651147 | 1.00 | CYP3A4 (0.51) | CYP3A4CYP2C9TAS1R3TAS1R1HINT1 | |
| SCHEMBL15827782 | 1.00 | CYP3A4 (0.51) | CYP3A4CYP2C9TAS1R3TAS1R1HINT1 | |
| SCHEMBL2515727 | 0.95 | CYP3A4 (0.58) | CYP3A4CYP2C9TAS1R3TAS1R1HINT1 | |
| SCHEMBL2515730 | 0.95 | CYP3A4 (0.58) | CYP3A4CYP2C9TAS1R3TAS1R1HINT1 | |
| SCHEMBL12202924 | 0.95 | CYP3A4 (0.58) | CYP3A4CYP2C9TAS1R3TAS1R1HINT1 | |
| SCHEMBL2515734 | 0.95 | CYP3A4 (0.58) | CYP3A4CYP2C9TAS1R3TAS1R1HINT1 | |
| SCHEMBL19537317 | 0.95 | CYP3A4 (0.58) | CYP3A4CYP2C9TAS1R3TAS1R1HINT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658616-B2 | Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2014-02-25 | — | — | US | disclosed |
| US-20110124592-A1 | NUCLEOSIDE ARYL PHOSPHORAMIDATES AND THEIR USE AS ANTI-VIRAL AGENTS FOR THE TREATMENT OF HEPATITUS C VIRUS | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124592-A1 | NUCLEOSIDE ARYL PHOSPHORAMIDATES AND THEIR USE AS ANTI-VIRAL AGENTS FOR THE TREATMENT OF HEPATITUS C VIRUS | PNP, NSUN2, MTAP | CYP3A4 1686/4885CYP2C9 1508/4885TAS1R3 4118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.